COMPANY PROFILE // THE 014 REPORT
Kalaris Therapeutics, Inc.
KLRS (Nasdaq) · Formerly: Allovir, Inc.; ViraCyte, Inc.
Assembled from 3 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
- Amber3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-07-20: a pattern of leadership change.
✓ SEC filings✗ LEI✗ SAM registration✗ IRS return✗ State registration✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no state registration, no website, no lobbying registration on record.
Kalaris Therapeutics, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), incorporated in DE, based in Berkeley Heights, NJ; listed as KLRS (Nasdaq).[source] It has filed 56 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-10.[source] Its largest institutional holders on 13F filings are SAMSARA BIOCAPITAL, LLC, RTW INVESTMENTS, LP, Alyeska Investment Group, L.P. (as of 2026-06-30).[source] Seraphix flags 1 item from these records: 3 8-K Item 5.02 filings (officer or director departures or appointments) in the last 12 months, most recently 2026-07-20.[source]
- red0
- amber1
- info0
- SAMSARA BIOCAPITAL, LLC$52.4M
- RTW INVESTMENTS, LP$5.3M
- Alyeska Investment Group, L.P.$2.3M
- Siren, L.L.C.$1.8M
- VANGUARD CAPITAL MANAGEMENT LLC$1.6M
- Ikarian Capital, LLC$1.5M
- UBS Group AG$1.1M
- RENAISSANCE TECHNOLOGIES LLC$608K
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Feinsod Matthew · Chief Medical Officer (Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Gall Matthew · Chief Financial Officer (Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- Hagen Brett R · Chief Accounting Officer (Officer) · latest Form 4 2026-03-23 · filing · LinkedIn search
- Oxtoby Andrew · See Remarks (Director,Officer) · latest Form 4 2026-03-20 · filing · LinkedIn search
- ADAMIS ANTHONY P · Director · latest Form 4 2025-04-11 · filing · LinkedIn search
- AKKARAJU SRINIVAS · Director,10% owner · latest Form 4 2026-02-17 · filing · LinkedIn search
- Dybbs Michael · Director · latest Form 4 2025-04-11 · filing · LinkedIn search
- Ferrara Napoleone · Director · latest Form 4 2025-04-11 · filing · LinkedIn search
- Hallal David · Director · latest Form 4 2025-04-11 · filing · LinkedIn search
- Jovan-Embiricos Morana · Director · latest Form 4 2025-04-11 · filing · LinkedIn search
- PATEL SAMIR CHANDRAKANT · Director · latest Form 4 2025-04-11 · filing · LinkedIn search
- PATTERSON LEONE D · Director · latest Form 4 2025-04-11 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- Wilmer Cutler Pickering Hale and Dorr LLP · Exhibit 5.1 legal opinion, S-3 filed 2026-04-03
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 26 CLEAR, 0 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001754068 | source |
| EIN | 83-1971007 | source |
| Business address (SEC) | 400 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922 | source |
Does not exist in the records we hold: LEI, UEI, NY DOS ID, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 131 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 176 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- SUTRO BIOPHARMA, INC. · Dybbs Michael
- SpyGlass Pharma, Inc. · Dybbs Michael
- Nkarta, Inc. · Dybbs Michael
- Scholar Rock Holding Corp · Hallal David
- Nkarta, Inc. · PATTERSON LEONE D
- Zymeworks Inc. · PATTERSON LEONE D
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-10 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-10 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-11 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-11 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-07-20 officer change 8-K items 5.02,9.01 · SEC EDGAR
- 2026-07-17 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-07-06 officer change 8-K items 5.02 · SEC EDGAR
- 2026-06-04 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-22 filing SCHEDULE 13D/A · SEC EDGAR
- 2026-05-12 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-12 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-24 filing ARS · SEC EDGAR
- 2026-04-24 filing DEFA14A · SEC EDGAR
- 2026-04-24 filing Proxy statement · SEC EDGAR
- 2026-04-13 filing EFFECT · SEC EDGAR
- 2026-04-13 filing EFFECT · SEC EDGAR
- 2026-04-13 filing 424B3 · SEC EDGAR
- 2026-04-13 filing 424B3 · SEC EDGAR
- 2026-04-10 officer change 8-K items 5.02 · SEC EDGAR
- 2026-04-09 filing CORRESP · SEC EDGAR
- 2026-04-09 filing CORRESP · SEC EDGAR
- 2026-04-08 filing UPLOAD · SEC EDGAR
- 2026-04-08 filing UPLOAD · SEC EDGAR
- 2026-04-03 filing S-3 · SEC EDGAR
- 2026-04-03 filing S-3 · SEC EDGAR
- 2026-03-20 filing 144 · SEC EDGAR
- 2026-03-17 filing S-8 · SEC EDGAR
- 2026-03-17 filing Annual report (10-K) · SEC EDGAR
- 2026-03-17 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-03-09 filing 8-K items 7.01,9.01 · SEC EDGAR
170 earlier entries
- 2026-02-17 filing SCHEDULE 13D/A
- 2025-12-22 filing SCHEDULE 13D/A
- 2025-12-18 filing 8-K items 1.01,3.02,8.01,9.01
- 2025-12-17 filing 8-K items 7.01,8.01,9.01
- 2025-11-12 filing Quarterly report (10-Q)
- 2025-11-12 filing 8-K items 2.02,9.01
- 2025-11-03 officer change 8-K items 5.02,9.01
- 2025-11-03 insider First Form 3/4/5 on record for Gall Matthew (Chief Financial Officer)
- 2025-08-13 filing Quarterly report (10-Q)
- 2025-08-13 filing 8-K items 5.07
- 2025-08-13 filing 8-K items 2.02,9.01
- 2025-07-01 filing ARS
- 2025-07-01 filing DEFA14A
- 2025-07-01 filing Proxy statement
- 2025-06-20 filing 8-K items 5.08,8.01
- 2025-06-04 filing S-8
- 2025-05-14 filing Quarterly report (10-Q)
- 2025-05-14 filing 8-K items 2.02,9.01
- 2025-04-16 officer change 8-K items 5.02,9.01
- 2025-04-11 insider First Form 3/4/5 on record for Feinsod Matthew (Chief Medical Officer)
- 2025-04-11 insider First Form 3/4/5 on record for Hagen Brett R (Chief Accounting Officer)
- 2025-04-11 insider First Form 3/4/5 on record for Oxtoby Andrew (See Remarks)
- 2025-04-11 insider First Form 3/4/5 on record for ADAMIS ANTHONY P (Director)
- 2025-04-11 insider First Form 3/4/5 on record for AKKARAJU SRINIVAS (Director,10% owner)
- 2025-04-11 insider First Form 3/4/5 on record for Dybbs Michael (Director)
- 2025-04-11 insider First Form 3/4/5 on record for Ferrara Napoleone (Director)
- 2025-04-11 insider First Form 3/4/5 on record for Hallal David (Director)
- 2025-04-11 insider First Form 3/4/5 on record for Jovan-Embiricos Morana (Director)
- 2025-04-11 insider First Form 3/4/5 on record for PATEL SAMIR CHANDRAKANT (Director)
- 2025-04-04 officer change 8-K items 5.02
- 2025-04-04 insider First Form 3/4/5 on record for PATTERSON LEONE D (Director)
- 2025-03-26 filing 3/A
- 2025-03-25 filing SCHEDULE 13D
- 2025-03-18 officer change 8-K items 2.01,2.02,5.01,5.02,5.03,5.06,7.01,9.01
- 2025-03-12 officer change 8-K items 5.02,5.07,8.01,9.01
- 2025-03-12 name change Name changed from Allovir, Inc.
- 2025-03-07 filing Annual report (10-K)
- 2025-02-28 filing 424B3
- 2025-02-24 filing 144
- 2025-02-24 filing 144
- 2025-02-24 filing 144
- 2025-02-10 filing SEC STAFF LETTER
- 2025-02-10 filing EFFECT
- 2025-02-10 filing 424B3
- 2025-02-06 filing CORRESP
- 2025-02-03 filing CORRESP
- 2025-02-03 filing S-4/A
- 2025-01-28 filing UPLOAD
- 2025-01-24 filing 144
- 2025-01-24 filing 144
- 2025-01-24 filing 144
- 2025-01-17 filing CORRESP
- 2025-01-17 filing S-4/A
- 2025-01-15 filing 425
- 2025-01-15 filing 8-K items 3.03,5.03,9.01
- 2025-01-10 filing 144
- 2025-01-10 filing 144
- 2025-01-10 filing 144
- 2025-01-10 filing 425
- 2025-01-10 filing 8-K items 8.01
- 2025-01-10 filing 425
- 2025-01-10 filing 8-K items 5.07
- 2025-01-07 filing SEC STAFF LETTER
- 2025-01-06 filing UPLOAD
- 2024-12-20 filing 425
- 2024-12-20 officer change 8-K items 5.02,9.01
- 2024-12-09 filing S-4
- 2024-12-09 filing 425
- 2024-12-06 filing Proxy statement
- 2024-11-26 filing PRE 14A
- 2024-11-19 filing 144
- 2024-11-19 filing 144
- 2024-11-19 filing 144
- 2024-11-19 filing 144
- 2024-11-12 filing Quarterly report (10-Q)
- 2024-11-08 filing 425
- 2024-11-08 filing 425
- 2024-11-08 filing 425
- 2024-11-08 filing 425
- 2024-11-08 filing 425
- 2024-11-08 filing 425
- 2024-11-08 filing 8-K items 1.01,7.01,9.01
- 2024-11-05 filing 144
- 2024-11-05 filing 144
- 2024-11-05 filing 144
- 2024-11-05 filing 144
- 2024-10-22 filing 144
- 2024-10-22 filing 144
- 2024-10-22 filing 144
- 2024-10-21 filing 144
- 2024-10-21 filing 144
- 2024-10-21 filing 144
- 2024-10-21 filing 144
- 2024-10-03 filing 144
- 2024-10-03 filing 144
- 2024-10-03 filing 144
- 2024-10-03 filing 144
- 2024-08-21 filing 144
- 2024-08-19 filing 144
- 2024-08-19 filing 144
- 2024-08-19 filing 144
- 2024-08-19 filing 144
- 2024-08-09 filing Quarterly report (10-Q)
- 2024-08-06 filing 144
- 2024-08-06 filing 144
- 2024-08-06 filing 144
- 2024-08-06 filing 144
- 2024-07-22 filing 144
- 2024-07-22 filing 144
- 2024-07-22 filing 144
- 2024-07-19 filing 144
- 2024-07-19 filing 144
- 2024-07-19 filing 144
- 2024-07-19 filing 144
- 2024-07-02 filing 144
- 2024-07-02 filing 144
- 2024-07-02 filing 144
- 2024-07-02 filing 144
- 2024-07-02 filing 8-K items 1.02,9.01
- 2024-06-11 filing 8-K items 1.02,9.01
- 2024-06-07 filing 8-K items 5.07
- 2024-06-03 officer change 8-K items 5.02
- 2024-05-21 filing 144
- 2024-05-17 filing 144
- 2024-05-17 filing 144
- 2024-05-17 filing 144
- 2024-05-17 filing 144
- 2024-05-13 filing Quarterly report (10-Q)
- 2024-05-03 filing 144
- 2024-05-03 filing 144
- 2024-05-03 filing 144
- 2024-05-03 filing 144
- 2024-04-23 filing ARS
- 2024-04-23 filing DEFA14A
- 2024-04-23 filing Proxy statement
- 2024-04-22 filing 144
- 2024-04-22 filing 144
- 2024-04-22 filing 144
- 2024-04-19 filing 144
- 2024-04-19 filing 144
- 2024-04-19 filing 144
- 2024-04-19 filing 144
- 2024-04-02 filing 144
- 2024-04-02 filing 144
- 2024-04-02 filing 144
- 2024-04-02 filing 144
- 2024-03-15 filing Annual report (10-K)
- 2024-02-21 filing 144
- 2024-02-20 filing 144
- 2024-02-20 filing 144
- 2024-02-20 filing 144
- 2024-02-20 filing 144
- 2024-02-15 filing RW
- 2024-02-12 filing 8-K items 3.01
- 2024-02-08 filing 144
- 2024-02-05 filing 144
- 2024-02-05 filing 144
- 2024-02-05 filing 144
- 2024-02-05 filing 144
- 2024-01-23 filing 144
- 2024-01-23 filing 144
- 2024-01-23 filing 144
- 2024-01-23 filing 144
- 2024-01-04 filing 144
- 2024-01-04 filing 144
- 2024-01-04 filing 144
- 2024-01-04 filing 144
- 2024-01-04 filing 8-K items 2.05
- 2023-12-27 filing 144
- 2023-12-22 filing 8-K items 7.01,8.01,9.01
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-10 (within 30 days) 10-Q filed
- 2026-11-10 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-13 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-11 (older) 10-Q filed
- 2026-08-11 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-20 (older) 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-07-17 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-07-06 (older) 8-K filed: Item 5.02 officer or director change
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-19; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:KLRS The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
0 possible matches held apart, matched by name only, not counted above; 2 records under a former name, shown apart.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1754068 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | KLRS / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 831971007 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001754068 | SEC EDGAR / IRS |
| CUSIP | 482929106 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001754068 | SEC EDGAR |
former name (shown apart, not merged) (2)
- former nameAlloVir · ClinicalTrials.gov
- former nameALLOVIR, INC. · State licences
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Net income (loss) (fiscal year ended 2025-12-31) | -$43,438,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-19 22:38 UTC | Report an error |
| Total assets (at 2025-12-31) | $121,736,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-19 22:38 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $78,814,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-19 22:38 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $98,054,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-19 22:38 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 22:38 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 22:38 UTC | Report an error |
| State of incorporation | DE | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 22:38 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 22:38 UTC | Report an error |
| Business address | 400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 22:38 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-19 22:38 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | -$38,370,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-19 22:38 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $200,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-19 22:38 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $1,448,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-19 22:38 UTC | Report an error |
| Form D total offering amount (D filed 2019-05-22) | $121,253,231 | 2019-05-22 | D | as filed | 2026-11-19 22:38 UTC | Report an error |
| Form D total amount sold (D filed 2019-05-22) | $121,253,231 | 2019-05-22 | D | as filed | 2026-11-19 22:38 UTC | Report an error |
| Form D industry group | Biotechnology | 2019-05-22 | D | as filed | 2026-11-19 22:38 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2019-05-22 | D | as filed | 2026-11-19 22:38 UTC | Report an error |
| Form D date of first sale | 2019-05-08 | 2019-05-22 | D | as filed | 2026-11-19 22:38 UTC | Report an error |
| Plan (pension, plan no. 001) | KALARIS THERAPEUTICS, INC. 401(K) RETIREMENT PLAN: 62 participants, assets $4,834,287 | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-19 22:38 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001193125-26-455378
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Net income (loss) | -$11,026,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-10 | 0001193125-26-455378 | 2026-11-19 22:38 UTC | Report an error |
| Interest expense | $0 | 3 months ended 2026-09-30 | 10-Q | 2026-11-10 | 0001193125-26-455378 | 2026-11-19 22:38 UTC | Report an error |
| Cash and cash equivalents | $47,384,000 | at 2026-09-30 | 10-Q | 2026-11-10 | 0001193125-26-455378 | 2026-11-19 22:38 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-10 Filing 10-Q filed
- 2026-11-10 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-10-13 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-11 Filing 10-Q filed
- 2026-08-11 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-07-20 Filing 8-K filed: Item 5.02 officer or director change; Item 9.01 exhibits
- 2026-07-17 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-07-06 Filing 8-K filed: Item 5.02 officer or director change
- 2026-06-04 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-12 Filing 10-Q filed
- 2026-05-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-24 Filing ARS filed
- 2026-04-24 Filing DEFA14A filed
- 2026-04-24 Filing DEF 14A filed
- 2026-04-13 Filing EFFECT filed
- 2026-04-13 Filing EFFECT filed
- 2026-04-13 Filing 424B3 filed
- 2026-04-13 Filing 424B3 filed
- 2026-04-10 Filing 8-K filed: Item 5.02 officer or director change
- 2026-04-09 Filing CORRESP filed
- 2026-04-09 Filing CORRESP filed
- 2026-04-08 Filing UPLOAD filed
- 2026-04-08 Filing UPLOAD filed
- 2026-04-03 Filing S-3 filed
- 2026-04-03 Filing S-3 filed
2 earlier entries
- 2026-03-17 Filing S-8 filed
- 2021-01-01 Record plan effective date: KALARIS THERAPEUTICS, INC. 401(K) RETIREMENT PLAN
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | SAMSARA BIOCAPITAL, LLC | $52,426,382 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
| 2 | RTW INVESTMENTS, LP | $5,291,000 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
| 3 | Alyeska Investment Group, L.P. | $2,330,836 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
| 4 | Siren, L.L.C. | $1,773,698 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | $1,622,758 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
| 6 | Ikarian Capital, LLC | $1,465,201 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
| 7 | UBS Group AG | $1,066,873 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
| 8 | RENAISSANCE TECHNOLOGIES LLC | $607,859 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
| 9 | MARSHALL WACE, LLP | $566,549 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | $464,287 | 2026-06-30 | SEC 13F filing | 2026-11-19 22:38 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1754068.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001754068. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.